Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180465 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
A Phase 2 study of Weight, sponsored by Neothetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 2
- Study locations
NCT01180465: Completed Phase 2 study of Weight, sponsored by Neothetics.
NCT01180465 is a Phase 2 study of Weight that has completed, run by Neothetics. The registered enrollment target is 160 participants, below the 356-participant average among 5 other Weight trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01180465, a Phase 2 study of Weight, has completed, sponsored by Neothetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
LIPO-102 is under evaluation for treatment of abdominal adiposity
Primary Outcome
physical exam, ECG, vital signs, clinical assessment is injection site, clinical laboratory tests, and adverse events
Conditions Studied
Interventions
- DRUG LIPO-102
- DRUG LIPO-102 Low
- DRUG LIPO-102, Placebo
Study Locations (2)
California
- - San Diego
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT01180465 record still lists
NCT01180465 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 356-participant average among 5 other Weight trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Weight appearing as the primary indexed condition, and to 3 interventions - of which LIPO-102 is the first listed.
NCT01180465 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT01180465 about?
NCT01180465 is a clinical study titled "A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity". LIPO-102 is under evaluation for treatment of abdominal adiposity
What is the current status of trial NCT01180465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2010-04. Estimated completion is 2010-09.
What conditions does trial NCT01180465 study?
This clinical trial studies the following conditions: Weight.
What interventions are being tested in trial NCT01180465?
The interventions under investigation include: LIPO-102 (DRUG), LIPO-102 Low (DRUG), LIPO-102, Placebo (DRUG).
Who is sponsoring clinical trial NCT01180465?
This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01180465 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial
RECRUITING · NA
-
PaTH Clinical Data Research Network (CDRN) Study of Healthy Lifestyles and Health Care
ACTIVE NOT RECRUITING
-
A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer
COMPLETED · NA
-
Weight Outlooks by Restriction of Diet and Sleep
COMPLETED · NA
-
Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia